drugset / Trial / NCT05455359
Gastrointestinal Dysmotility on Aspiration Risk
RandomizedCrossoverTriple-blindTreatment
Summary
The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.
Timeline
- Start
- 2025-02-13
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famotidine | Other / unclassified | 0.4 mg/kg | — |
| Subject | Prucalopride | Small molecule | 0.04 mg/kg | — |